In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 85 for your search:
Drug:  bendamustine hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO22468, 2009-012072-28, NCT01056510
2.

Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100917, BENDAMUSCLL4001, NCT01739491
3.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GAO4753g, GO01297, NCT01059630
4.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 110918, NCT01077518
5.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1931008, 3129K5-3303, NCT01232556
6.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BDM3502, 2010-022102-41, NCT01289223
7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: RV-FOL-GELARC-0683C, 2011-002792-42, NCT01476787
8.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GS-US-312-0115, NCT01569295
9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: RGB-NHL, NCT01570049
10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C18083/3076, NCT01596621
11.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100840, PCI-32765CLL3001, 2012-000600-15, U1111-1135-3745, NCT01611090
12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RV-FOL-GELARC-0683, 2011-002792-42, NCT01650701
13.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: RGN0117, NCT01657955
14.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: OMB114578, 2011-000919-22, 009988575, NCT01678430
15.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GS-US-313-0125, NCT01732926
16.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 65 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100967, PCI-32765MCL3002, U1111-1137-0389, 2012-004056-11, NCT01776840
17.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Other
Protocol IDs: F080929010, UAB 0818, NCT00856830
18.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SAKK 38/08, SWS-SAKK-38/08, EUDRACT-2009-012559-67, EU-20976, CDR0000652127, NCT00987493
19.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: NLG-MCL4, NCT00963534
20.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: RBP-01/08, OSHO77, NCT01002703
21.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MMRC-020-021, NCI-2009-01535, 09-004211, C18083/6125, NCT01049945
22.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 341, NCT01078142
23.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: 2009-0546, NCT01096992
24.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PSOC 2502, NCI-2010-00907, NCT01165112
25.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MM08-141, NCT01177683
1     
New Search